Progyny price target lowered to $30 from $48 at Barclays

Barclays lowered the firm’s price target on Progyny to $30 from $48 and keeps an Overweight rating on the shares. The company reported a meaningful miss in Q1 and guidance cut attributed to softer utilization, the analyst tells investors in a research note. The firm says that while management credibility has taken a step back, it does not think this is indicative of Progyny’s underlying business quality.